2023 Bradyarrhythmias Pacing Guidelines: Key Indications and Protocols

Abstract

The management of bradyarrhythmias and cardiac conduction disorders is continuously refined by evidence from major clinical trials, necessitating regular updates to clinical practice guidelines. 

This review summarizes the key recommendations from the 2023 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) Guideline for the Management of Patients with Bradycardia and Cardiac Conduction Delay, alongside relevant European Society of Cardiology (ESC) positions. 

The primary focus is on Class I indications for permanent pacemaker implantation in patients with symptomatic sinus node dysfunction (SND) and acquired atrioventricular (AV) block. A major update involves the emphasis on conduction system pacing (CSP)—specifically His-Bundle Pacing (HBP) and Left Bundle Branch Area Pacing (LBBAP)—as an alternative to conventional right ventricular pacing, particularly in those with reduced left ventricular ejection fraction. 

This article provides cardiologists and electrophysiologists with a focused, evidence-based synopsis of contemporary protocols for pacing device selection, programming, and follow-up, facilitating guideline-concordant care.

Introduction

Bradyarrhythmias and cardiac conduction disorders represent a significant portion of the global cardiovascular disease burden, contributing to syncope, fatigue, heart failure, and mortality. 

These conditions are characterized by abnormally slow heart rates or defects in the electrical impulse propagation, often requiring the implantation of a permanent pacemaker. The prevalence increases substantially with age and in patients with underlying structural heart disease, diabetes, or renal dysfunction.

Timely and guideline-adherent management is crucial to optimizing patient outcomes, minimizing morbidity, and improving quality of life. 

The 2023 update to the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS) guidelines, developed in collaboration with key international bodies, synthesizes robust evidence from recent large-scale randomized controlled trials (RCTs). 

This article reviews these pivotal recommendations, offering a clinical framework for practitioners to apply the current Class I indications for pacing and integrate emerging techniques, particularly conduction system pacing (CSP), into routine practice.

Diagnosis and Risk Stratification of Bradyarrhythmias

Accurate diagnosis of the underlying bradyarrhythmia is paramount for determining the necessity and timing of permanent pacing. The evaluation relies on a comprehensive assessment of symptoms, electrocardiogram (ECG) findings, and, often, prolonged rhythm monitoring or electrophysiological (EP) study.

Sinus Node Dysfunction (SND)

Sinus Node Dysfunction (SND), historically termed sick sinus syndrome, is characterized by the failure of the sinus node to generate or transmit impulses appropriately. 

Diagnostic criteria are founded on the correlation of clinical symptoms—such as syncope, pre-syncope, dizziness, or fatigue—with ECG evidence of severe bradycardia, sinus pauses ( ≥ 3 seconds), or chronotropic incompetence.

• Clinical Presentation: Patients may present with intermittent symptoms due to paroxysmal episodes of bradycardia or prolonged pauses.
  
  
• Diagnostic Evaluation: Diagnosis is confirmed by continuous or intermittent rhythm monitoring (e.g., Holter, mobile cardiac telemetry, or implantable loop recorder) demonstrating the bradyarrhythmia linked to the patient’s symptoms. Chronotropic incompetence, defined as the inability to achieve ≥ 85% of the maximal predicted heart rate during exercise, is an important Class I indicator for pacing in symptomatic patients.
  
  

Atrioventricular (AV) Block

Atrioventricular (AV) block refers to the impaired conduction of impulses from the atria to the ventricles. Classification is based on the severity and location of the conduction delay, which dictates the urgency and type of intervention.

• Classification: AV block is categorized into First-Degree (prolonged PR interval), Second-Degree (Type I, Wenckebach; Type II, Mobitz), and Third-Degree (complete AV dissociation).
  
  
• Second-Degree AV Block Type II (Mobitz II) and Third-Degree AV Block: These represent high-grade, often infra-Hisian blocks associated with a high risk of progression to asystole or severe bradycardia. The 2023 guidelines maintain a Class I recommendation for pacing in patients with Third-Degree or symptomatic Second-Degree Mobitz II AV block, regardless of symptoms.
  
  
• The Role of His-Bundle or Infra-Hisian Conduction Assessment: In cases of chronic, asymptomatic Mobitz Type I block, or in the context of fascicular block, an electrophysiologic (EP) study may be warranted to assess the location of the block. A finding of a prolonged H-V interval ( ≥ 70 ms) or infra-Hisian block on EP study is a key risk stratifier for progression to complete heart block, guiding prophylactic pacing decisions.
  
  

Guideline-Driven Indications for Permanent Pacing

The decision to implant a permanent pacemaker is predicated on a careful assessment of symptoms, severity of the conduction disturbance, and prognosis. 

The current guidelines utilize a Class of Recommendation (COR I, IIa, IIb, III) and Level of Evidence (LOE A, B-R, B-NR, C-LD, C-EO) framework to standardize clinical decision-making.

Pacing in Symptomatic Sinus Node Dysfunction

Permanent pacing is warranted for symptomatic Sinus Node Dysfunction (SND) to relieve debilitating symptoms and improve quality of life.

• Class I Indications: Pacing is indicated for symptomatic bradycardia due to SND, including sinus arrest, sinoatrial block, or persistent severe sinus bradycardia (heart rate typically < 40 beats/min or pauses ≥ 3 seconds) when these are clearly attributable to the patient’s symptoms (e.g., syncope or near-syncope).
  
  
• Chronotropic Incompetence: Pacing is also Class I for patients with chronotropic incompetence—the inability to increase heart rate adequately with exercise or effort—who have symptoms attributable to this condition.
  
  
• Practice Highlight: Defining Symptomatic: The cornerstone of a Class I recommendation for SND is the symptom-rhythm correlation. Pacing is generally not indicated (Class III) for asymptomatic patients, regardless of the severity of bradycardia or pauses.
  
  

Pacing in Acquired Atrioventricular Block

The indications for AV block are less dependent on symptoms, reflecting the potentially life-threatening nature of high-grade block.

• Class I Indications for High-Grade Block: Pacing is a Class I recommendation for:
  • Third-Degree AV Block (Complete Heart Block): Regardless of symptoms or site of block.
    
    
  • Second-Degree Mobitz Type II AV Block: Regardless of symptoms or site of block.
    
    
  • Alternating Bundle Branch Block.
    
    
• Symptomatic Second-Degree AV Block: Pacing is Class I for symptomatic Second-Degree AV Block of any type, provided the symptoms are directly correlated to the rhythm disturbance.
  
  
• Prophylactic Pacing: Pacing is indicated (Class I) for AV block that occurs after catheter ablation or surgical procedures that are not expected to resolve.
  
  

Pacing in Chronic Bifascicular and Trifascicular Block

While many patients with fascicular block are asymptomatic and do not require pacing, specific findings warrant intervention due to the high risk of sudden progression to complete heart block.

• Class I Indications: Pacing is indicated for patients with chronic bifascicular block or trifascicular block who experience unexplained syncope, provided that an EP study confirms an underlying infra-Hisian conduction delay (e.g., prolonged H-V interval ≥ 70 ms) or an inability to conduct to the ventricles during rapid atrial pacing.
  
  
• Electrophysiologic Study (EP Study): The EP study serves as a critical risk stratifier, determining the prognosis and necessity of prophylactic pacing in this subgroup.
  
  

Pacing Modalities and Device Programming

The selection of the pacing modality and its subsequent programming significantly impact patient outcomes, particularly concerning the avoidance of unnecessary Right Ventricular (RV) pacing, which can lead to pacing-induced cardiomyopathy.

Selecting the Appropriate Pacing Mode

The choice of pacing mode (VVI, AAI, DDD) is guided by the underlying rhythm disorder and the integrity of the intrinsic conduction system.

• Dual-Chamber Pacing (DDD/R): This is the preferred mode for most patients with Atrioventricular (AV) block and normal sinus node function. DDD pacing preserves AV synchrony, which is crucial for maximizing cardiac output.
  
  
• Single-Chamber Ventricular Pacing (VVI/R): VVI is generally reserved for patients with chronic atrial fibrillation and slow ventricular rates, or in select patients with isolated SND who have pre-existing high-grade AV block, as it does not require an atrial lead.
  
  
• Single-Chamber Atrial Pacing (AAI/R): AAI is appropriate for patients with pure Sinus Node Dysfunction (SND) who have demonstrably normal AV conduction.
  
  
• RV Pacing Minimization: Algorithms designed to minimize unnecessary RV pacing (e.g., AAI to DDD mode switching, or Managed Ventricular Pacing [MVP]) are Class IIa recommendations. The goal is to maximize intrinsic AV conduction time to prevent the detrimental effects of long-term RV apical pacing on left ventricular function.
  
  

Advanced Pacing Techniques

The 2023 guidelines place significant emphasis on pacing strategies that maintain or restore physiological electrical activation, mitigating the risks associated with conventional RV apical pacing.

• Conduction System Pacing (CSP): CSP, primarily His-Bundle Pacing (HBP) and Left Bundle Branch Area Pacing (LBBAP), involves implanting the lead directly into or near the native conduction system, resulting in a narrow QRS complex and more physiological ventricular activation.
  
  
  • Evidence Review: CSP is increasingly recognized as a viable alternative to conventional pacing, particularly in patients who require high percentages of ventricular pacing or those with pre-existing reduced Left Ventricular Ejection Fraction (LVEF). Data from studies like the HIS-SYNC Trial support the functional benefits of CSP in preventing the reduction of LVEF seen with chronic RV pacing.
    
    
  • Guideline Position: CSP is considered a Class IIa recommendation as an alternative to RV pacing to prevent pacing-induced cardiomyopathy, especially in patients with anticipated high pacing burden.
    
    

Device Programming Considerations

Optimal programming is necessary for efficacy and safety. Key parameters include:

• Lower Rate Limit (LRL): Should be programmed to prevent symptoms, typically 50–60 beats/min. In cases of chronotropic incompetence, rate-responsive (R) functions should be activated.
  
  
• Upper Tracking Rate (UTR): Set to prevent rapid ventricular pacing during supraventricular arrhythmias, typically 120–140 beats/min.
  
  
• AV Delay: Careful adjustment of the programmed AV delay is critical to ensure optimal hemodynamic function. Dynamic or rate-adaptive AV delays are often used to mimic natural physiology.
  
  

Management in Special Populations and Clinical Settings

The indications and protocols for permanent pacing may require modification based on patient demographics, comorbid conditions, and acute clinical events.

Bradycardia Following Myocardial Infarction or Cardiac Surgery

High-grade atrioventricular (AV) block or sinus node dysfunction (SND) can occur acutely in the setting of myocardial infarction (MI) or cardiac surgery. The decision for permanent pacing depends on the expected reversibility of the conduction defect.

• Following Acute MI: Transient bradyarrhythmias, particularly in the setting of inferior wall MI, may resolve within days. Permanent pacing is indicated (Class I) if Third-Degree or Mobitz Type II AV block persists beyond the immediate acute phase (typically ≥ 5 days) or if the block occurs at the infra-Hisian level. Transient pacing may be required initially.
  
  
• Post-Cardiac Surgery: New-onset persistent high-grade AV block following cardiac valve replacement or septal procedures warrants permanent pacing if it does not resolve within a reasonable observation period (e.g., 7–14 days). Temporary pacing wires should be used to bridge this period.
  
  

Management of Pacing in Athletes and the Elderly

Specific physiological differences necessitate tailored programming in these groups.

• Athletes: Symptomatic bradycardia in competitive athletes is rare, but when present, it may require pacing. Programmed pacing rates must be customized to avoid rate competition during exercise while ensuring chronotropic competence. Consideration of rate-responsive functions is crucial for optimal performance. The presence of bradycardia alone, without symptoms, is generally not an indication for pacing (Class III).
  
  
• The Elderly: This population often has multiple comorbidities and is more susceptible to the hemodynamic effects of ventricular pacing. Dual-chamber pacing is often preferred, but the need for rate-responsive features (activity sensors) must be carefully assessed based on the patient’s actual mobility and functional status.
  
  

Drug-Induced Bradycardia

A significant proportion of iatrogenic bradyarrhythmias is caused by essential cardiovascular medications, such as beta-blockers, non-dihydropyridine calcium channel blockers, and antiarrhythmics.

• Assessment: If symptomatic bradyarrhythmia is present and the causative drug is essential (e.g., for refractory angina or post-MI management) and cannot be reasonably substituted or reduced, permanent pacing is indicated (Class I/IIa). This allows the safe continuation of life-prolonging or necessary pharmacological therapy.
  
  
• Protocol: Every effort should be made to reduce the dosage, discontinue the drug, or switch to an alternative agent before proceeding to permanent device implantation. The necessity of the medication must be weighed against the risks of pacing and the potential for device-related complications.
  
  

Clinical Practice Summary and Key Takeaways

The 2023 pacing guidelines reinforce the fundamental principle that pacemaker implantation must correlate the underlying bradyarrhythmia with symptomatic compromise or a demonstrably high risk of sudden progression to advanced block. The primary advances focus on the adoption of physiological pacing techniques to minimize long-term ventricular dysfunction.

Practice Highlights: Summary of Class I Pacing Recommendations

Key Takeaways for Clinical Practice

1. Symptom Correlation is Mandatory for SND: Clinicians must prioritize the objective linkage between the observed rhythm disturbance and patient symptoms (syncope, dizziness) before implanting a device for Sinus Node Dysfunction.
   
   
2. Shift Towards Physiological Pacing: The guidelines support the consideration of Conduction System Pacing (CSP), including His-Bundle Pacing (HBP) and Left Bundle Branch Area Pacing (LBBAP), as a strategy to mitigate the risk of pacing-induced cardiomyopathy, especially in patients anticipated to have high-percentage ventricular pacing.
   
   
3. High-Grade Block is an Absolute Indication: Third-degree AV block and Mobitz Type II block remain Class I indications for pacing regardless of the patient’s acute symptomatic status.